{"protocolSection":{"identificationModule":{"nctId":"NCT06910358","orgStudyIdInfo":{"id":"DISC-1459-301"},"secondaryIdInfos":[{"id":"2024-520407-27-00","type":"CTIS"}],"organization":{"fullName":"Disc Medicine, Inc","class":"INDUSTRY"},"briefTitle":"Study of Bitopertin in Participants With EPP or XLP (APOLLO)","officialTitle":"APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)","acronym":"APOLLO"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-04-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-03-17","studyFirstSubmitQcDate":"2025-03-27","studyFirstPostDateStruct":{"date":"2025-04-04","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-11","lastUpdatePostDateStruct":{"date":"2026-02-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Disc Medicine, Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are:\n\n* Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP.\n* How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment.\n\nResearchers will compare bitopertin to a placebo look-alike substance that contains no drug.\n\nParticipants will complete daily questionnaires and attend study visits for assessments."},"conditionsModule":{"conditions":["Erythropoietic Protoporphyria (EPP)","X-Linked Protoporphyria (XLP)"],"keywords":["EPP","XLP","DISC-1459","RO4917838","porphyria"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":150,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"DISC-1459 oral dose","type":"EXPERIMENTAL","interventionNames":["Drug: DISC-1459"]}],"interventions":[{"type":"DRUG","name":"Placebo","description":"Oral dose, once a day for 24 weeks","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"DISC-1459","description":"Oral dose, once a day for 24 weeks","armGroupLabels":["DISC-1459 oral dose"],"otherNames":["Bitopertin","RO4917838"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatment","timeFrame":"24 weeks"},{"measure":"Percent change from baseline in whole-blood metal-free PPIX levels at 6 months","timeFrame":"24 weeks"},{"measure":"Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment period","timeFrame":"24 weeks"}],"secondaryOutcomes":[{"measure":"Occurrence of phototoxic reactions over the 6-month treatment period","timeFrame":"24 weeks"},{"measure":"Cumulative total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) over the 6-month (24-week) treatment period","timeFrame":"24 weeks"},{"measure":"Change from baseline in 2-week average daily sunlight exposure time (minutes) to first prodromal symptom (eg, burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at 6 months","timeFrame":"24 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged 12 years or older at the time of study consent.\n2. Diagnosis of EPP or XLP, based on medical history by ferrochelatase (FECH) or aminolevulinic acid synthase 2 (ALAS2) genotyping or by biochemical porphyrin analysis.\n3. Minimum daily Sun Exposure Diary compliance ≥85% on Days -14 through Day -1, inclusive, during screening, and at least 1 successfully completed Sun Exposure Challenge (adults only, as this assessment is optional for adolescents) or historical recall of time to prodrome\n4. Body weight ≥32 kg (ages 12 to \\<18 years), body mass index ≥18.5 kg/m2 (ages ≥18 years) at screening.\n5. Washout of at least 2 months prior to screening of afamelanotide and dersimelagon, if applicable.\n6. Aspartate aminotransferase and alanine transaminase \\<3× upper limit of normal (ULN)and total bilirubin \\<2× ULN (unless documented Gilbert syndrome) at screening. Albumin \\>lower limit of normal (LLN).\n7. Willing to practice highly effective methods of birth control (both males who have partners of childbearing potential and females of childbearing potential during screening, while taking study drug, and for at least 30 days after the last dose of study drug).\n\nExclusion Criteria:\n\n1. Major surgery within 8 weeks before screening or incomplete recovery from any previous surgery.\n2. Other than EPP or XLP, an inherited intrinsic or extrinsic red cell disease associated with anemia.\n3. Known hypersensitivity to any component of the study drug.\n4. History of liver transplantation or anticipated need for liver transplantation.\n5. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.\n6. Active human immunodeficiency virus (HIV), active hepatitis B or C.\n7. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study.\n8. Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.\n\n   Treatment History:\n9. Prior exposure to bitopertin.\n10. Concurrent or planned treatment with afamelanotide or dersimelagon during the study period.\n11. Treatment with opioids for any period \\>7 days in the 2 months prior to screening or anticipated to require opioid use for \\>7 days at any point during the study.\n12. New treatment for anemia, including initiation of iron supplementation, within 1 month of screening.\n13. Current or planned use of any drugs or herbal remedies known to be strong or moderate inhibitors or inducers of cytochrome P450 (CYP)3A4 enzymes for 28 days prior to the first dose and throughout the study.\n14. Current or planned treatment with antipsychotic medication.\n\n    Laboratory Exclusions:\n15. Hemoglobin \\<10 g/dL at screening.\n\n    Miscellaneous:\n16. Participation in other interventional clinical studies within 30 days prior to screening.\n17. If female, pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Disc Medicine Clinical Trials","role":"CONTACT","phone":"(617) 674 9274","email":"clinicaltrials@discmedicine.com"}],"overallOfficials":[{"name":"Will Savage, MD, PhD","affiliation":"Disc Medicine","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Marvel Clinical Research","status":"RECRUITING","city":"Huntington Beach","state":"California","zip":"92647","country":"United States","contacts":[{"name":"Matthew Campos","role":"CONTACT","phone":"714-375-5970","email":"info@marvelclinical.com"},{"name":"Manuchehr Darani, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"University of California San Francisco","status":"RECRUITING","city":"San Francisco","state":"California","zip":"94143","country":"United States","contacts":[{"name":"Jackie Lam","role":"CONTACT","phone":"415-502-7750","email":"Jacqueline.lam@ucsf.edu"},{"name":"Bruce Wang, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"University of Miami Miller School of Medicine","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33146","country":"United States","contacts":[{"name":"Felisa Padilla","role":"CONTACT","phone":"305-243-7343","email":"fcp25@med.miami.edu"},{"name":"Cynthia Levy, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Massachusetts General Hospital","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02115","country":"United States","contacts":[{"name":"Narmene Bensaber","role":"CONTACT","phone":"206-681-0218","email":"nbensaber@mgh.harvard.edu"},{"name":"Amy Dickey, MD, MSC","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"MetroBoston Clinical Partners","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02135","country":"United States","contacts":[{"name":"Stella Schandorf","role":"CONTACT","phone":"781-535-1174","email":"gzhang@metrobostoncp.com"},{"name":"Mark S Amster, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Henry Ford Health System","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","contacts":[{"name":"Jennifer Creasor","role":"CONTACT","phone":"313-916-0427","email":"jcreaso2@hfhs.org"},{"name":"Tasneem Mohammad, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Mount Sinai Hospital","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","contacts":[{"name":"Georgia MacDonald","role":"CONTACT","phone":"646-946-6923","email":"georgia.macdonald@mssm.edu"},{"name":"Manisha Balwani, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Wake Forest University","status":"RECRUITING","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","contacts":[{"name":"Dee Faust","role":"CONTACT","phone":"336-713-1442","email":"Denise.Faust@advocatehealth.org"},{"name":"Herbert Bonkovsky, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Remington-Davis Clinical Research","status":"RECRUITING","city":"Columbus","state":"Ohio","zip":"43215","country":"United States","contacts":[{"name":"Imani Ramos","role":"CONTACT","phone":"614-487-2560","email":"derm@remdavis.com"},{"role":"CONTACT","email":"iramos@remdavis.com"},{"name":"Edward M Cordasco, DO, FCCP","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"University of Texas Medical Branch","status":"RECRUITING","city":"Galveston","state":"Texas","zip":"77550","country":"United States","contacts":[{"name":"Rochelle Simmons","role":"CONTACT","phone":"409-772-9103","email":"rrsimmon@utmb.edu"},{"name":"Karl Anderson, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.30135,"lon":-94.7977}},{"facility":"University of Washington","status":"RECRUITING","city":"Seattle","state":"Washington","zip":"98195","country":"United States","contacts":[{"name":"Cassidy McCarthy","role":"CONTACT","phone":"206-606-2446","email":"cmcca140@fredhutch.org"},{"name":"Sioban Keel, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Royal Prince Alfred Hospital","status":"RECRUITING","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","contacts":[{"name":"Darcie Kavanagh","role":"CONTACT","phone":"(02) 9515 5186","email":"darcie.kavanagh@health.nsw.gov.au"},{"name":"A/Prof Peter Stewart","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"The Royal Melbourne Hospital","status":"RECRUITING","city":"Parkville","state":"Victoria","zip":"3050","country":"Australia","contacts":[{"name":"Dermatology Research","role":"CONTACT","phone":"+61393424542","email":"dermatologyresearch@mh.org.au"},{"name":"A/Prof Gayle Ross","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"University of Alberta","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T6G 2R3","country":"Canada","contacts":[{"name":"Principle Investigator","role":"CONTACT","phone":"780-492-3550","email":"Bruce.Ritchie@ualberta.ca"},{"name":"Bruce Ritchie","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"CHU de Nantes - Hôtel Dieu, Service de dermatologie","status":"RECRUITING","city":"Nantes","state":"France","zip":"44093","country":"France","contacts":[{"name":"Dr. Marie Le Moigne","role":"CONTACT","phone":"+33 2 44 76 83 90","email":"marie.lemoigne@chu-nantes.fr"},{"name":"Dr. Marie Le Moigne","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard","status":"RECRUITING","city":"Paris","state":"France","zip":"75018","country":"France","contacts":[{"name":"Jonathan Lehacaut","role":"CONTACT","phone":"+ 33 1 40 25 68 75","email":"jonathan.lehacaut@aphp.fr"},{"name":"Laurent Gouya","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Charité - Universitätsmedizin Berlin, Institute of Allergology","status":"RECRUITING","city":"Berlin","state":"Germany","zip":"12203","country":"Germany","contacts":[{"name":"Principle Investigator","role":"CONTACT","phone":"+49 30 450 518214","email":"manuel.pereira@charite.de"},{"name":"Manuel Pereira","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Klinikum Chemnitz gGmbH","status":"RECRUITING","city":"Chemnitz","state":"Saxony","zip":"09116","country":"Germany","contacts":[{"name":"Dr med. Ilja Kubisch","role":"CONTACT","phone":"0371 333-33236","email":"i.kubisch@skc.de"},{"name":"Dr med. Ilja Kubisch","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":50.8357,"lon":12.92922}},{"facility":"Erasmus MC","status":"RECRUITING","city":"Rotterdam","state":"The Netherlands","zip":"3015 GD","country":"Netherlands","contacts":[{"name":"Janneke Langendonk","role":"CONTACT","phone":"+31 (0)10 7040574","email":"EPP@erasmusmc.nl"},{"name":"Janneke Langendonk","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Helse Bergen","status":"RECRUITING","city":"Bergen","state":"Norway","zip":"5032","country":"Norway","contacts":[{"name":"Study Coordinator","role":"CONTACT","phone":"+47 55973170","email":"porfyri@helse-bergen.no"},{"name":"Aasne Karine Aarsand","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":60.39299,"lon":5.32415}},{"facility":"Hospital Clinic de Barcelona","status":"RECRUITING","city":"Barcelona","state":"Spain","zip":"08036","country":"Spain","contacts":[{"name":"Pablo Iglesias García","role":"CONTACT","phone":"+34 93 227 98 67","email":"piglesia@recerca.clinic.cat"},{"name":"Paula Aguilera Peiro","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Karolinska University Hospital","status":"RECRUITING","city":"Stockholm","state":"Sweden","zip":"141 86","country":"Sweden","contacts":[{"name":"Staffan Wahlin, MD, Associate Professor","role":"CONTACT","phone":"+468585 87984","email":"staffan.wahlin@ki.se"},{"name":"Staffan Wahlin, MD, Associate Professor","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":59.32938,"lon":18.06871}},{"facility":"Guy's and St Thomas' NHS Foundation Trust","status":"RECRUITING","city":"London","state":"England","zip":"SE1 9RT","country":"United Kingdom","contacts":[{"name":"Neil Songsong","role":"CONTACT","phone":"077 1769 7435","email":"prince.songsong@nhs.net"},{"role":"CONTACT","email":"DermatologyTrials@gstt.nhs.uk"},{"name":"Robert Sarkany","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D046351","term":"Protoporphyria, Erythropoietic"},{"id":"C567464","term":"Protoporphyria, Erythropoietic, X-Linked Dominant"},{"id":"D011164","term":"Porphyrias"}],"ancestors":[{"id":"D017094","term":"Porphyrias, Hepatic"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D012873","term":"Skin Diseases, Genetic"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C550631","term":"(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone"}]}},"hasResults":false}